Response to: "Quantifying the effect of vaccination on transmission in modelling studies".

Autor: Bartsch SM; Public Health Informatics, Computational, and Operations Research (PHICOR), CUNY Graduate School of Public Health and Health Policy, New York City, NY, USA.; Center for Advanced Technology and Communication in Health (CATCH), CUNY Graduate School of Public Health and Health Policy, New York City, NY, USA., O'Shea KJ; Public Health Informatics, Computational, and Operations Research (PHICOR), CUNY Graduate School of Public Health and Health Policy, New York City, NY, USA.; Center for Advanced Technology and Communication in Health (CATCH), CUNY Graduate School of Public Health and Health Policy, New York City, NY, USA., Strych U; National School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USA., Bottazzi ME; National School of Tropical Medicine, Department of Pediatrics, and Texas Children's Hospital Center for Vaccine Development, Baylor College of Medicine, Houston, TX, USA.; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, USA., Lee BY; Public Health Informatics, Computational, and Operations Research (PHICOR), CUNY Graduate School of Public Health and Health Policy, New York City, NY, USA.; Center for Advanced Technology and Communication in Health (CATCH), CUNY Graduate School of Public Health and Health Policy, New York City, NY, USA.; Pandemic Response Institute, New York City, NY, USA.
Jazyk: angličtina
Zdroj: EClinicalMedicine [EClinicalMedicine] 2024 Jun 06; Vol. 73, pp. 102670. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024).
DOI: 10.1016/j.eclinm.2024.102670
Abstrakt: Competing Interests: SMB, KJO, and BYL have nothing to disclose. US and MEB report: I am the co-inventor of a protein vaccine technology owned by my employer, Baylor College of Medicine (BCM) that was licensed non-exclusively and with no patent restrictions to several companies committed to advance vaccines for low- and middle-income countries. The co-inventors have no involvement in license negotiations conducted by BCM. Similar to other research universities, a long-standing BCM policy provides its faculty and staff, who make discoveries that result in a commercial license, a share of any royalty income. MEB is a co-director of the Lancet Covid-19 Task Force on Vaccines and Therapeutics.
Databáze: MEDLINE